Skip to main content
Clinical Trials/NCT01491165
NCT01491165UnknownPhase 2

Safety and Efficacy of Umbilical Cord Mesenchyma Stem Cell Transplantation in Liver Cirrhosis Patients

General Hospital of Chinese Armed Police Forces1 site in 1 country75 target enrollmentStarted: December 1, 2011Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Sponsor
Enrollment
75
Locations
1
Primary Endpoint
liver volume calculated by MRI

Study Overview

Brief Summary

Mainstream of current treatment of liver cirrhosis is liver transplantation, but there are high cost, risk and immune rejection and other issues. Umbilical cord mesenchyma stem cell with self-and directed differentiation capacity can effectively rescue experimental liver failure and contribute to liver regeneration, which suggests the feasibility of stem cell transplantation therapy. In this study, the safety and efficacy of umbilical cord mesenchyma stem cell transplantation through interventional procedures in patients liver cirrhosis will be evaluated.

Detailed Description

This study included three research centers, each center were carried out 25 cases of liver cirrhosis in patients with stem cell transplantation. All the selection and exclusion criteria are same, data summary and analysis will be complete by the epidemiological commissioner.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Clinical diagnosis of liver cirrhosis;
  • Without hepatic encephalopathy;
  • No ascites or have easily dissipated ascites;
  • Value of bilirubin is less than 100;
  • Value of albumin is greater than 16 g / L;
  • Prothrombin time is less than 21 seconds;

Exclusion Criteria

  • Severe cardiovascular disease, and immunocompromised patients;
  • Patients with localized lesions affecting graft infection;
  • Coagulation disorders;
  • Liver nodules more than 2cm or Liver cancer

Outcomes

Primary Outcomes

liver volume calculated by MRI

Time Frame: 3 days before transplantation, 6 and 12 months after transplantation

Instrument:universal 1.5 Tesla superconducting MRI instrument. Slice thickness :2mm.

Secondary Outcomes

  • liver biopsy(whinin 7 days before transplantation, 6 and 12 months after transplantation)
  • liver enzyme fiber spectrum(whinin 7 days before transplantation, 1,3,6 and 12 months after transplantation)
  • portal vein and splenic vein measure(whinin 7 days before transplantation, 1,3,6 and 12 months after transplantation)
  • blood biochemistry(whinin 7 days before transplantation, 1,3,6 and 12 months after transplantation)
  • coagulation(whinin 7 days before transplantation, 1,3,6 and 12 months after transplantation)
  • blood test(whinin 7 days before transplantation, 1,3,6 and 12 months after transplantation)
  • gastroscopy(whinin 7 days before transplantation, 6 and 12 months after transplantation)

Investigators

Sponsor
General Hospital of Chinese Armed Police Forces
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Safety and Efficacy of Stem Cell... | Clinical Trial